CN103948736B - The compound Chinese medicinal preparation for the treatment of hepatocarcinoma and production method thereof - Google Patents
The compound Chinese medicinal preparation for the treatment of hepatocarcinoma and production method thereof Download PDFInfo
- Publication number
- CN103948736B CN103948736B CN201410147463.0A CN201410147463A CN103948736B CN 103948736 B CN103948736 B CN 103948736B CN 201410147463 A CN201410147463 A CN 201410147463A CN 103948736 B CN103948736 B CN 103948736B
- Authority
- CN
- China
- Prior art keywords
- medicine
- ethanol
- concentration
- medicinal
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 150000001875 compounds Chemical class 0.000 title claims abstract description 34
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 17
- 238000011282 treatment Methods 0.000 title claims description 42
- 239000003814 drug Substances 0.000 claims abstract description 149
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 129
- 239000007788 liquid Substances 0.000 claims abstract description 122
- 239000000843 powder Substances 0.000 claims abstract description 28
- 239000002775 capsule Substances 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 13
- 238000003809 water extraction Methods 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 8
- 239000008187 granular material Substances 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 238000010438 heat treatment Methods 0.000 claims description 30
- 239000000706 filtrate Substances 0.000 claims description 29
- 238000001816 cooling Methods 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 21
- 238000010992 reflux Methods 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 13
- 229920002472 Starch Polymers 0.000 claims description 12
- 239000008107 starch Substances 0.000 claims description 12
- 235000019698 starch Nutrition 0.000 claims description 12
- -1 Opadry tm type Substances 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 238000011084 recovery Methods 0.000 claims description 9
- 238000012869 ethanol precipitation Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 6
- 238000002481 ethanol extraction Methods 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 230000007246 mechanism Effects 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 229960004793 sucrose Drugs 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 239000003292 glue Substances 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 238000005538 encapsulation Methods 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 229960004016 sucrose syrup Drugs 0.000 claims description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 238000005453 pelletization Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 37
- 206010028980 Neoplasm Diseases 0.000 abstract description 27
- 230000001093 anti-cancer Effects 0.000 abstract description 21
- 201000011510 cancer Diseases 0.000 abstract description 20
- 239000008280 blood Substances 0.000 abstract description 16
- 210000004369 blood Anatomy 0.000 abstract description 16
- 230000009471 action Effects 0.000 abstract description 8
- 239000012141 concentrate Substances 0.000 abstract description 7
- 108010017842 Telomerase Proteins 0.000 abstract description 6
- 230000004913 activation Effects 0.000 abstract description 6
- 230000017531 blood circulation Effects 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 241000411851 herbal medicine Species 0.000 abstract description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 3
- 230000006907 apoptotic process Effects 0.000 abstract description 3
- 230000005907 cancer growth Effects 0.000 abstract description 3
- 206010017758 gastric cancer Diseases 0.000 abstract description 3
- 201000011549 stomach cancer Diseases 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- 239000002244 precipitate Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 43
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 21
- 201000009030 Carcinoma Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 201000010099 disease Diseases 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 201000007270 liver cancer Diseases 0.000 description 9
- 208000014018 liver neoplasm Diseases 0.000 description 9
- 231100000614 poison Toxicity 0.000 description 9
- 230000006870 function Effects 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000010297 uvangoletin Substances 0.000 description 6
- 241000208340 Araliaceae Species 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000008434 ginseng Nutrition 0.000 description 5
- 229930182470 glycoside Natural products 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- GUAFOGOEJLSQBT-UHFFFAOYSA-N scoparone Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 241000222336 Ganoderma Species 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- HOEVRHHMDJKUMZ-UHFFFAOYSA-N Isofraxidin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2OC HOEVRHHMDJKUMZ-UHFFFAOYSA-N 0.000 description 3
- ANCHXLMTFNOVDK-UHFFFAOYSA-N Isofraxidin Natural products COC1=C(O)C(OC)=CC2=C1OC=CC2=O ANCHXLMTFNOVDK-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000006286 aqueous extract Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 210000004681 ovum Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- LJLXBYGPGVKTBK-NRLMIDHWSA-N (1S,7R,8S,9S,10R,12S)-7,8-dihydroxy-4,9-dimethyl-13-methylidene-6-oxatetracyclo[7.4.0.03,7.010,12]tridec-3-en-5-one Chemical compound CC1=C2C[C@H]3C(=C)[C@H]4C[C@H]4[C@]3(C)[C@H](O)[C@]2(O)OC1=O LJLXBYGPGVKTBK-NRLMIDHWSA-N 0.000 description 2
- ORJDDOBAOGKRJV-CQSZACIVSA-N (2S)-Pinocembrin Natural products C1([C@H]2CC(=O)C3=C(O)C=C(C=C3O2)OC)=CC=CC=C1 ORJDDOBAOGKRJV-CQSZACIVSA-N 0.000 description 2
- FMIMFCRXYXVFTA-FUAOEXFOSA-N (4as,6ar,6as,6br,8ar,12ar,14bs)-2,2,6a,6b,9,9,12a-heptamethyl-10-oxo-3,4,5,6,6a,7,8,8a,11,12,13,14b-dodecahydro-1h-picene-4a-carboxylic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C FMIMFCRXYXVFTA-FUAOEXFOSA-N 0.000 description 2
- CKEXCBVNKRHAMX-UHFFFAOYSA-N 5-hydroxy-4',7-dimethoxyflavanone Chemical compound C1=CC(OC)=CC=C1C1OC2=CC(OC)=CC(O)=C2C(=O)C1 CKEXCBVNKRHAMX-UHFFFAOYSA-N 0.000 description 2
- 241000448435 Acalypha australis Species 0.000 description 2
- 241000271039 Agkistrodon Species 0.000 description 2
- 241000746375 Andrographis Species 0.000 description 2
- FBMORZZOJSDNRQ-GLQYFDAESA-N Atractylenolide III Chemical compound C=C([C@@H]1C2)CCC[C@]1(C)C[C@@]1(O)C2=C(C)C(=O)O1 FBMORZZOJSDNRQ-GLQYFDAESA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 241000259759 Cassida nobilis Species 0.000 description 2
- 241001550206 Colla Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- ORJDDOBAOGKRJV-UHFFFAOYSA-N Dihydrotectochrysin Natural products O1C2=CC(OC)=CC(O)=C2C(=O)CC1C1=CC=CC=C1 ORJDDOBAOGKRJV-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000283956 Manis Species 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000003005 anticarcinogenic agent Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- LJLXBYGPGVKTBK-UHFFFAOYSA-N chloranthalactone E Natural products CC1=C2CC3C(=C)C4CC4C3(C)C(O)C2(O)OC1=O LJLXBYGPGVKTBK-UHFFFAOYSA-N 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 2
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- YCOZIPAWZNQLMR-UHFFFAOYSA-N pentadecane Chemical compound CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 description 2
- 229930015704 phenylpropanoid Natural products 0.000 description 2
- ORJDDOBAOGKRJV-AWEZNQCLSA-N pinostrobin Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)OC)=CC=CC=C1 ORJDDOBAOGKRJV-AWEZNQCLSA-N 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 210000001243 pseudopodia Anatomy 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000009286 sanguis draxonis Substances 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- KAPZSMYEZDLAFB-UHFFFAOYSA-N tambulin Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(OC)C(OC)=C2O1 KAPZSMYEZDLAFB-UHFFFAOYSA-N 0.000 description 2
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000759 toxicological effect Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 150000003648 triterpenes Chemical group 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- AJDSYFQMQGZVPS-TWNGIMQYSA-N (2s)-2-[(3r,8s,9r,10r,13r,14s,16r,17r)-3-[(2s,3r,4s,5r)-4-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-16-hydroxy-4,4,9,13,14-pentamethyl-11-oxo-1,2,3, Chemical compound O1C(C(C)C)=CC(=O)[C@]1(C)[C@@H]1[C@@]2(C)CC(=O)[C@@]3(C)[C@H](CC[C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@H](O)[C@@H](O)[C@H](C)O5)O)[C@H](O)CO4)O)C4(C)C)C4=CC[C@H]3[C@]2(C)C[C@H]1O AJDSYFQMQGZVPS-TWNGIMQYSA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- FMIMFCRXYXVFTA-UHFFFAOYSA-N 3-Oxo-12-oleanen-28-oic acid Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C FMIMFCRXYXVFTA-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 244000296912 Ageratum conyzoides Species 0.000 description 1
- 235000004405 Ageratum conyzoides Nutrition 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 201000003126 Anuria Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000269417 Bufo Species 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 235000016535 Capraria biflora Nutrition 0.000 description 1
- 241000131329 Carabidae Species 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- 241000758719 Chloranthaceae Species 0.000 description 1
- 241000721156 Chloranthus spicatus Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241001450685 Corallium japonicum Species 0.000 description 1
- 241000660877 Coridius Species 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 240000009087 Crescentia cujete Species 0.000 description 1
- 235000005983 Crescentia cujete Nutrition 0.000 description 1
- LNSXRXFBSDRILE-UHFFFAOYSA-N Cucurbitacin Natural products CC(=O)OC(C)(C)C=CC(=O)C(C)(O)C1C(O)CC2(C)C3CC=C4C(C)(C)C(O)C(O)CC4(C)C3(C)C(=O)CC12C LNSXRXFBSDRILE-UHFFFAOYSA-N 0.000 description 1
- CVKKIVYBGGDJCR-SXDZHWHFSA-N Cucurbitacin B Natural products CC(=O)OC(C)(C)C=CC(=O)[C@@](C)(O)[C@@H]1[C@@H](O)C[C@]2(C)C3=CC[C@@H]4C(C)(C)C(=O)[C@H](O)C[C@@]4(C)[C@@H]3CC(=O)[C@@]12C CVKKIVYBGGDJCR-SXDZHWHFSA-N 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 241000006479 Cyme Species 0.000 description 1
- GSFDOOHGKOHDEL-UHFFFAOYSA-N Dalpanitin Natural products COc1cc(ccc1O)C2=COc3c(C4OC(CO)C(O)C(O)C4O)c(O)cc(O)c3C2=O GSFDOOHGKOHDEL-UHFFFAOYSA-N 0.000 description 1
- FBMORZZOJSDNRQ-UHFFFAOYSA-N Demethoxy,B,HCl-Adriamycin Natural products C1C2C(=C)CCCC2(C)CC2(O)C1=C(C)C(=O)O2 FBMORZZOJSDNRQ-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000221017 Euphorbiaceae Species 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 241001312741 Gekko swinhonis Species 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- HYBIDSYXKTYHCM-BXLXJPJESA-N Istanbulin A Chemical compound C1[C@]2(O)OC(=O)C(C)=C2C[C@@]2(C)[C@H](C)CCC(=O)[C@@H]21 HYBIDSYXKTYHCM-BXLXJPJESA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 235000009797 Lagenaria vulgaris Nutrition 0.000 description 1
- 241000254023 Locusta Species 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000124079 Mylabris Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010034487 Pericarditis constrictive Diseases 0.000 description 1
- 241001375216 Picria Species 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 241000222640 Polyporus Species 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 241000736026 Sarcandra Species 0.000 description 1
- 240000004274 Sarcandra glabra Species 0.000 description 1
- 235000010842 Sarcandra glabra Nutrition 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 241000522620 Scorpio Species 0.000 description 1
- 241001530126 Scrophularia Species 0.000 description 1
- 241000207844 Scrophulariaceae Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000019229 Spleen disease Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- FYPYWIYWMVCNCS-UHFFFAOYSA-N Uvangoletin Chemical compound COC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=CC=C1 FYPYWIYWMVCNCS-UHFFFAOYSA-N 0.000 description 1
- PDZBWDAJMIPJSK-UHFFFAOYSA-N Uvangoletin Natural products COC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 PDZBWDAJMIPJSK-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 208000011279 abdominal lump Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002115 aflatoxin B1 Substances 0.000 description 1
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 1
- 229930020125 aflatoxin-B1 Natural products 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- VQKFNUFAXTZWDK-UHFFFAOYSA-N alpha-methylfuran Natural products CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 201000003465 angular cheilitis Diseases 0.000 description 1
- 230000003171 anti-complementary effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- OAXKIRPCKWQWOQ-UHFFFAOYSA-N atractylenolide III Natural products CC1=C2CC3C(CCCC3=C)CC2(O)OC1=O OAXKIRPCKWQWOQ-UHFFFAOYSA-N 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- WOOVZFPAOYYLSV-UHFFFAOYSA-N biisofraxidin Natural products COc1cc2cc(-c3cc4cc(OC)c(O)c(OC)c4oc3=O)c(=O)oc2c(OC)c1O WOOVZFPAOYYLSV-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 208000007287 cheilitis Diseases 0.000 description 1
- 230000010109 chemoembolization Effects 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000000839 constrictive pericarditis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 150000001904 cucurbitacins Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- PIGAXYFCLPQWOD-UHFFFAOYSA-N dihydrocucurbitacin I Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)CCC(C)(O)C)C(O)CC3(C)C1CC=C1C2C=C(O)C(=O)C1(C)C PIGAXYFCLPQWOD-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 235000021038 drupes Nutrition 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- FFDHYUFECJTEAY-UHFFFAOYSA-N epimacherinic acid Natural products CC1(C)CCC2(CCC3(C)C(CCC4C5(C)CCCC(C)(C)C5CCC34C)C2C1)C(=O)O FFDHYUFECJTEAY-UHFFFAOYSA-N 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000010135 fructus aurantii immaturus Substances 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000003864 humus Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- HYBIDSYXKTYHCM-UHFFFAOYSA-N istanbulin A Natural products C1C2(O)OC(=O)C(C)=C2CC2(C)C(C)CCC(=O)C21 HYBIDSYXKTYHCM-UHFFFAOYSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- AJDSYFQMQGZVPS-KCWQJKHFSA-N picfeltarraenin IV Natural products O([C@@H]1[C@@H](O)[C@H](O[C@H]2C(C)(C)C=3[C@H]([C@]4(C)C(=O)C[C@]5(C)[C@H]([C@H](O)C[C@@]5(C)[C@@H]4CC=3)[C@]3(C)C(=O)C=C(C(C)C)O3)CC2)OC[C@H]1O)[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1 AJDSYFQMQGZVPS-KCWQJKHFSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000003303 reheating Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- SVHDRHWULLNMQC-UHFFFAOYSA-N scoparone Natural products C1=CC(=O)OC2=C1C=C(C(=O)C)C(C(C)=O)=C2 SVHDRHWULLNMQC-UHFFFAOYSA-N 0.000 description 1
- 239000009490 scorpio Substances 0.000 description 1
- 230000008117 seed development Effects 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000027140 splenic disease Diseases 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical class C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 239000003020 ursodeoxycholic acid derivative Substances 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008539 xiaoyao Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of compound Chinese medicinal preparation treating hepatocarcinoma and production method thereof, its Chinese herbal medicine primary raw material parts by weight are: containing 1 15 parts of pearl in leaf, Herba Sarcandrae 5 30 parts, Herba vallisneriae Spiralis 5 15 parts, Radix Scrophulariae 5 15 parts, its production method is by said medicine water extraction, precipitate with ethanol concentrates, the modern pharmaceutical production technologies such as powder process make oral liquid, capsule, tablet, granule etc., this Chinese medicine preparation has dispelling wind and removing obstruction in the collateral, the effects such as blood circulation promoting and blood stasis dispelling, and have cancer suppressing action, it passes through anticancer telomerase activation, make cancerous cell telomeric dna replicate to slow down and be gradually shortened, growth of cancer cells slows down, it is eventually striking to apoptosis, it is applicable to hepatocarcinoma, gastric cancer etc..
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation treating cancer, particularly treat compound Chinese medicinal preparation and the production thereof of hepatocarcinoma
Method.
Background technology
Primary hepatocarcinoma (primary liver cancer, PLC) refers to hepatoma carcinoma cell or the cytogenetic cancer of stones in intrahepatic bile duct,
For one of China's common cancer, its mortality rate is 20.4/10 ten thousand, accounts for the 18.8% of national malignant tumor death, is only second to stomach
Cancer, occupies second.The whole world has 110,000 people to die from hepatocarcinoma every year.Guangxi Hepatocellular mortality rate is 27.31/10 ten thousand, flat higher than the whole nation
All levels.The investigation report of the different regions, 20th century Chinese countryside eighties that univ cambridge uk pan issued according to 2006,
Analyze 67 county's hepatocarcinoma case fatality rate situations of China, find that the different geographical age is issued significantly different.Epidemiological study shows,
The reason of onset of liver cancer and viral hepatitis, drinking-water, diet (as in food containing aflatoxin B1 etc.) etc. factor relevant, but closely
Year research shows, the sudden change having multiple gene is relevant with hepatocarcinoma, and finally goes back neither one conclusion certainly, still falls within morbidity former
Because of not clear, the disease of complicated mechanism, hence without a kind of method of radical cure, current Therapeutic Method substantially has operative treatment, aunt
Breath property surgical intervention, multimodal Comprehensive Treatment, transcatheter hepatic arterial chemoembolization (TAE), anhydrous alcohol intratumor injection, radiotherapy,
The methods such as targeted therapy, chemotherapy, Biotherapeutics, treatment by Chinese herbs.TCM Literature does not has the name of disease of " hepatocarcinoma ", clinical according to it
Performance, can belong to " costalgia ", " gathering ", " jaundice ", " expansion " etc..Ancients' cloud " without long-pending, empty people then has it to strong people ".Typically recognize
For, tumor is that the stagnation of QI, blood stasis, expectorant are solidifying, poison is poly-and are formed due to positive QI-insufficiency, visceral dysfunction.The disease of hepatocarcinoma
Machine generally speaking deficiency in origin and excess in superficiality, with insufficiency of the spleen for this, the stagnation of QI, blood stasis, heresy damp and hot, malicious are mark.Clinically, country variant has difference
Research experience, has again different emphasis.Yu Shi thinks: insufficiency of the spleen for this, due to insufficiency of the spleen existence, the most just have the stagnation of QI, blood stasis,
Damp and hot, so that the appearance of the deficiency of YIN.Qian Shi then thinks: insufficiency of the spleen stagnation of liver-QI is this, and early metaphase is attached most importance to stagnation of liver-QI, and middle and advanced stage with insufficiency of the spleen is
Very.Pan Shi thinks: " ecchymosis, void " is the basic pathogenesis of deficiency of the liver.Upper abdominal lump, hepatalgia are the objective evidence of " stasis of blood ";Hepatocarcinoma
Development is fast, and change of illness state is fierce, and B-mode and infection with hepatitis C virus, flavacin and contaminated drinking water are the main diseases of hepatocarcinoma
Cause, these broadly fall into the category of the traditional Chinese medical science " malicious ";The common poor appetite of hepatocarcinoma patient, abdominal distention, Mental fatigue, weak, nausea,vomiting,diarrhea, disappear
Insufficiency of the spleen disease such as thin;And the stasis of blood, poison, empty three all the time and deposit, reciprocal causation, vicious cycle, through the hepatocarcinoma course of disease.In treatment
Aspect, the method that the traditional Chinese medical science uses has: determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, treatment based on differentiation of disease, folk prescription proved recipe, external treatment etc..In recent years use Chinese medicine or
Therapy of combining Chinese and Western medicine primary hepatocarcinoma, achieves large development and certain curative effect, before presenting anticancer gratifying of Chinese medicine
Scape, but still suffer from many problems.As lacked unified CM syndrome differentiation criterion and curative effect judging standard, the dynamic of verification recognizes the most not
Enough, Therapeutic Method also lacks standardization etc..Chinese medicine preparation about treatment hepatocarcinoma (or other cancers) is more, such as:
1. [ autograph ] Chinese medicine is main treatment advanced primary liver cancer 30 example clinical observation.[ author ] appoints sword, Zhu Li
Beautiful.[ periodical name ] Jiangxi Chinese medicine, 1999;30(5): 21.[ digest ] 30 example mid and late liver cancer patient, is divided into stagnation of liver-QI with deficiency of the spleen, the stagnation of QI
Blood stasis, dampness-heat in the liver and gallbladder, weakened body resistance stasis four type, control respectively with soothing liver and strengthening spleen (XIAOYAO POWDER plus-minus), blood circulation promoting and blood stasis dispelling (Ramulus Cinnamomi Poria pill conjunction
Bupleurum powder for relieving liver-qi is added and subtracted), the method for removing toxic substances removing dampness function of gallbladder promoting (Decoction of Gentiana for Purging the Liver-fire close Herba Artemisiae Scopariae Decoction plus-minus), result patient is the shortest for life cycle
2 months, the longest 78 months, median survival interval 5.75 months, 3 months persons of survival rate are 76.67%, and within 1,2,3,5 years, person is respectively
25.59%、16.56%、11.04%、7.36%。
2. [ autograph ] treats 128 example primary hepatocarcinoma from plan tortoise beetle Bai Longtang.[ author ] Wang Donghui.[ periodical name ] Liaoning traditional Chinese medical science
Magazine, 1998;14(9): 5.[ digest ] treats liver cancer patient 128 example from intending tortoise beetle Bai Longtang, with card plus-minus, result: clinic is controlled
More, effective each 5 examples, account for 4%, effective 79 examples, account for 62%, invalid 39 examples, account for 30%.
3. [ autograph ] Herba Hyperici Japonici treatment primary hepatocarcinoma 30 example.[ author ] Sun Zhongyi.[ periodical name ] combination of Chinese and Western medicine hepatopathy is miscellaneous
Will, 1995;5(4): 29.[ digest ] Herba Hyperici Japonici treatment primary hepatocarcinoma 30 example, result clinical symptoms is clearly better, and B ultrasonic, CT examine
Look into, each 8 examples of the person of turning out cloudy after treatment.
4. [ autograph ] Agkistrodon treatment primary hepatocarcinoma.[ author ] Xu Hefang.[ periodical name ] Zhejiang College Of Traditional Chinese Medicine journal, 1992;16
(1): 28.[ digest ] treats primary hepatocarcinoma 4 example, result survival more than 14 years and 6 years each 1 examples of person, 2 years person 2 examples of surviving with Agkistrodon.
5. [ autograph ] plaster for treating cancerous pain external application for curing hepatocarcinoma pain 46 example.[ author ] Hu Huaiqiang, Li Jie.[ periodical name ] external treatment with Chinese medicine is miscellaneous
Will, 1998;7(2): 18.[ digest ] plaster for treating cancerous pain (Thallus Laminariae (Thallus Eckloniae), Sargassum, Ganoderma etc. form) external application hepatic region, treating the liver cancer pain 46 example, result
Effective (pain disappearance) 36 examples, take a turn for the better (pain relief) 10 example, total effective rate 100%.
6. the progress of [ autograph ] Herba Sarcandrae.[ author ] Lu Songgui.[ periodical name ] Chinese crude drug, 2001;24(8): 606.[ digest ]
The 373 various tumor patients of example are used 'Zhongjiefeng ' to carry out clinical observation by 17 clinical units such as Xuhui District Central Hospital, Shanghai,
Total effective rate is 53.9%, and obvious effective rate is 15.3%, wherein 113 example alone this product treatment, and effective percentage is 62.8%, and obvious effective rate is 22.1%.
7. [ inscribe one's name ] effect and the toxicity of ZHONGJIEFENG ZHUSHEYE anti-mouse hepatoma cell HepA-22.[ author ] Sun Wenjuan, Li Jing,
Lan Fengying, etc..[ periodical name ] Chinese patent medicine, 2008;25(4): 313 [ digest ] ZHONGJIEFENG ZHUSHEYE body is interior, external to rat liver cancer
HepA-22 and glandular stomach PC cell are respectively provided with antitumor action.
8. [ autograph ] ZHONGJIEFENG ZHUSHEYE treatment cancerous pain 60 example.[ author ] Yang Huanbiao.[ periodical name ] China Pharmaceutical,
2008;17(20): 90 example middle and advanced stage canurous ache patients are divided into two groups by 59 [ digests ], all use Three ladders analgesia treatment,
Treatment group (60 example) adds uses ZHONGJIEFENG ZHUSHEYE, and result: total effective rate treatment group is 85.0%, matched group (30 example) is 60.0%.
Some medical facility and medical personnel have delivered the more public affairs utilizing Chinese herbal treatment hepatopathy or hepatocarcinoma in recent years
Open document report, such as:
1, Chinese patent, title: a kind of Chinese medicine preparation treating hepatocarcinoma, application number: CN201110009652.8 applies for
Day: open (bulletin) day: the 2011.06.01 of 2011.01.17, open (bulletin) number: CN102078409A, applies for (patent
Power) people: Traditional Chinese Medicine University Of Guangzhou, Zeli Medicine Science-Technology Co., Ltd., Guangzhou, summary: the present invention relates to medical configuration product, tool
Body relates to a kind of Chinese medicine preparation treating hepatocarcinoma, and said preparation is made up of the acceptable adjuvant of active ingredient and medical science, wherein said
Active ingredient be made up of following crude drug by mass percentage: Cacumen Securinegae Suffruticosae 5-30%, Radix Sophorae Flavescentis 5-20%, Herba Rabdosiae Lophanthoidis 5-
30%, Radix Notoginseng 4-10%, Radix Salviae Miltiorrhizae 5-25%, Semen Persicae 4-15%, Radix Bupleuri 4-10%, Fructus Ligustri Lucidi 5-25%, Herba Ecliptae 5-25%, too
Son ginseng 2-25%, Radix Glycyrrhizae 2-10%.Above-mentioned 11 tastes share, gather altogether heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, dispersing the stagnated live-QI to relieve the stagnation of QI and strengthening spleen, tonifying kidney it
Effect, and then suppression tumor growth, reach to treat the purpose of hepatocarcinoma.
2, Chinese patent, title: a kind of Chinese medicine preparation treating hepatocarcinoma and preparation method thereof, application number:
The CN201110003318.1 applying date: 2011.01.10, open (bulletin) number: CN102078569A open (bulletin) day:
2011.06.01, apply for (patent right) people: Li Xiuju;Summary: a kind of Chinese medicine preparation treating hepatocarcinoma, in described Chinese medicine preparation
The ratio of weight and number of various crude drug can be: Radix Et Caulis Acanthopanacis Senticosi 10~20 parts, Herba Hedyotidis Diffusae 10~20 parts, the Radix Astragali 10~20 parts,
Resina garciniae 10~20 parts, Fructus Ligustri Lucidi 10~20 parts, the Rhizoma Atractylodis Macrocephalae 10~20 parts, Radix Polygoni Multiflori Preparata 10~20 parts, Herba Artemisiae Scopariae 10~20 parts, Rhizoma Curcumae Longae 10~
20 parts, Spica Prunellae 10~20 parts, Polyporus 10~20 parts, Fructus Schisandrae Chinensis 10~20 parts, Rhizoma Curcumae 10~20 parts, Poria 10~20 parts, ink
Fructus seu radix camptothecae acuminatae (Fructus Camptothecae Acuminatae) 10~20 parts, Radix Salviae Miltiorrhizae 10~20 parts, the Radix Paeoniae Alba 10~20 parts, Herba Scutellariae Barbatae 10~20 parts, Radix Scutellariae 10~20 parts, Herba Epimedii 10~
20 parts, Venenum Bufonis 1~10 parts, Scorpio 1~10 parts.Have the advantages that and inoperable patient can be extended life cycle.Right
Patient with operation, radiotherapy, chemotherapy as main treatment can play auxiliary treatment effect, to hepatopathy background hepatitis specific to hepatocarcinoma with
Liver cirrhosis, also has certain curative effect.
3, Chinese patent, title: the Chinese medicine preparation for the treatment of hepatocarcinoma, application number: the CN201210063149.5 applying date:
2012.03.11, open (bulletin) day: the 2012.07.04 of open (bulletin) number: CN102526638A, applies for (patent right)
People: Qin Deguang;Summary: a kind of Chinese medicine preparation treating hepatocarcinoma, this Chinese medicine preparation comprises: the Radix Aucklandiae, Rhizoma Curcumae, the Rhizoma Atractylodis Macrocephalae, Radix Gentianae,
Rhizoma Alismatis, Radix Curcumae, Radix Bupleuri, Semen Arecae, Pericarpium Citri Reticulatae Viride, Pericarpium Arecae, Fructus Aurantii, Herba Scutellariae Barbatae, Herba Lobeliae Chinensis, Herba Solani Nigri, Carapax et Plastrum Testudinis, Carapax Trionycis, Squama Manis, male
Oyster, Spica Prunellae, Herba Hedyotidis Diffusae.Inventor have passed through more than 40 year and puts into practice, improves, improves and clinical proves, has that curative effect is fast, nothing
Side effect, reduction patient medical expense, total effective rate about 90%.
4, Chinese patent, title: a kind of anticancer dispersing tumor toxin expelling soup Application Number (patent): CN200410038090.X Shen
Please apply for (patent by open (bulletin) day: the 2005.11.23 of day: 2004.05.19, open (bulletin) number: CN1698684
Power) people: the big address of clock: Linhe West Road, Guangzhou City, Guangdong Province 89 Guangzhou out-patient department of Friendship Hospital invention (design) people: clock
Big summary: a kind of anticancer dispersing tumor toxin expelling soup, uses and has heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, the Chinese medicine of anticancer dispersing tumor effect, wherein
With animal drugs such as Bufo siccus, ground beetle, Hirudo, Mylabris, Gekko Swinhonis as principal agent, be aided with the Radix Astragali, Radix Ginseng, Ganoderma, Radix Notoginseng, the Rhizoma Atractylodis Macrocephalae, Rhizoma Sparganii,
Chinese herbal medicine is fried forms for Rhizoma Curcumae, Semen Persicae, Flos Carthami, Herba Hedyotidis Diffusae etc..The present invention both can directly kill tumor cell, destroys focus knot
Closing, antiviral, antiinflammatory, destruction tumor vessel can prevent cell from shift again, anti-cell suddenlys change, improves cellular informatics pipeline,
The drug resistance of reversing tumor cell, improves body's immunity simultaneously, thus effectively treats various innocent and malignant tumour, especially treat
Hepatocarcinoma, pulmonary carcinoma, breast carcinoma best results.
5, Chinese patent, title: a kind of Chinese medicine composition treating liver cirrhosis disease and preparation method thereof, application is (specially
Profit) number: open (bulletin) number: the CN101869686A of the CN200910309349.2 applying date: 2009.11.05, open (public
Accusing) day: 2010.10.27 apply for (patent right) people: safe one and company limited of Pu (Beijing) Chinese medicine study institute, address: northern
No. 16 No. 9 building 2027B invention (design) people: Wang Feng summaries of the rich pipeline in Jing Shi Fengtai District: a kind of Chinese medicine treating liver cirrhosis disease
Compositions and preparation method thereof, Chinese medicine composition is mainly made up of following crude drug: Sanguis Draxonis, Squama Manis, Rhizoma Chuanxiong, Radix Paeoniae Rubra, the Radix Paeoniae Alba, Fu
Siberian cocklebur, the Rhizoma Atractylodis Macrocephalae, Semen Persicae, Flos Carthami, Ganoderma, Sanguis Draxonis, Rhizoma Corydalis, Radix Angelicae Sinensis, Rhizoma Sparganii, Rhizoma Curcumae, Pericarpium Citri Reticulatae, Fructus Aurantii Immaturus, Radix Et Rhizoma Rhei, Radix Ginseng, Radix Astragali, ripe
Radix Rehmanniae, Radix Puerariae, Colla Plastri Testudinis, Cornu Cervi Degelatinatum, Colla carapax Trionycis, Radix Rehmanniae, Radix Scrophulariae, Fructus Corni, the Radix Linderae, Fructus Aurantii, Rhizoma Cyperi, Pericarpium Citri Reticulatae, the Radix Aucklandiae, heavy
Perfume, Cortex Magnoliae Officinalis, Fructus Evodiae, Bulbus Allii Macrostemonis, Aspongopus.Chinese medicine composition of the present invention can be prepared as any according to conventional method of Chinese medicinal
A kind of conventional oral formulations.It is main that the present invention can significantly improve lassitude and weak, loss of appetite and dyspepsia, can have nauseating, detest
Oil, abdominal part flatulence, epigastric discomfort, dull pain and diarrhoea, ordinary circumstance are poor with nutriture, become thin weak, lassitude, serious symptom
Person is weak and is unable to leave the bed, and coarse with xerosis cutis, and complexion is gloomy pitch-dark, anemia, glossitis, angular cheilitis, nyctalopia, multiple
Neuritis and edema and water and the symptom such as electrolyte disturbance, portal hypertension, clinical efficacy is definite, evident in efficacy, takes effect rapidly.
The Chinese medicine preparation for the treatment of cancer disclosed above, achieves gratifying effect, but still suffers from many shortcomings, as lacked
Unified CM syndrome differentiation criterion and curative effect judging standard, Therapeutic Method also lacks standardization, and the life extending patient also falls short of.
Summary of the invention
Present invention aim to address that the Chinese medicine preparation for the treatment of cancer at present lacks unified CM syndrome differentiation criterion and Outcome measure
Standard, Therapeutic Method lacks standardization, extends the problems such as the life of patient falls short of, it is provided that one has dispelling wind and removing obstruction in the collateral, work
The effects such as blood and dissolving stasis, curative effect is obvious, extends life time longer, safety, the Chinese medicine preparation having no side effect and production method thereof.
The present invention treats what the compound Chinese medicinal preparation principle active component of hepatocarcinoma was made up of the raw material of Chinese medicine of following parts by weight:
Ye Li 5-15 part on pearl;
Herba Sarcandrae 5-30 part;
Herba vallisneriae Spiralis 5-15 part;
Radix Scrophulariae 5-15 part.
Above Chinese medicine all can find its another name or Latin from Chinese medicine pharmacopeia or Chinese herbal medicine handbook, Chinese periodical, with
And the place of production, function, usage.For understanding the drug action mechanism of the present invention, take passages each Chinese medicinal ingredients and performance be as follows:
1. containing pearl in leaf: (Acalypha australis L.), also known as hiding pearl, Acalypha australis, people Herba Amaranthi tricoloris, Herba Acalyphae in leaf
Deng, for annual or perennial herb or shrub, belonging to a lot of money section (Euphorbiaceae) plant, the whole world there are about 450 kinds, extensively
It is distributed in the torrid zone, the world, subtropical zone.China there are about 17 kinds, with the most common containing pearl in leaf, and all herbal medicine, there is heat clearing away profit
Wet, effect of hemostasis convergence, among the people for treating diarrhea due to damp-heat disease, skin eczema, cough, hemorrhage, the disease such as have blood in stool, Guangdong is among the people also
Have for treating cancer.This group proves from anticancer experiment, and hepatoma cell strain is grown to have and significantly suppresses and lead by folk prescription Aqueous extracts
Causing apoptotic effect, clinical have obvious therapeutic effect to oral cancer etc.;With hybrid combinations such as Herba Sarcandraes, effect is remarkably reinforced.
Chemical composition: terpenoid and steroidal compounds (such as betulinic acid etc.), organic acid (such as gallic acid etc.), flavonoid
(such as rutin etc.), quinones, alkaloid, soft quality etc..
Pharmacological action: 1. wound, treating for skin disease;2. antioxidation, the experiment of this group proves, Aqueous extracts has significantly
Remove superoxide anion radical effect;3. antibacterial action;4. antitumaous effect, the experiment of this group and clinical proof, aqueous extract has
Significantly cancer suppressing action.
2. Herba Sarcandrae: [ Sarcandra glabra (Thunb.) Nakai ], has another name called Herba Pileae Scriptae, Herba Pileae Scriptae, Herba Pileae Scriptae, joint
Bone tea, connect chu lan tree etc., be the herb of Chloranthaceae plant plait Corallium Japonicum Kishinouye, be the Pharmacopoeia of the People's Republic of China 2000,2005
The legal medical material that version is recorded.On the south the Changjiang river, all there is distribution each province, can artificial growth.Nature and flavor with return through Herba Sarcandrae bitter in the mouth, pungent, property
Flat, GUIXIN, Liver Channel.Function with cure mainly: there is clearing away heat and cooling blood, blood circulation promoting and dispersing pathogen accumulation, dispelling wind and removing obstruction in the collateral effect.Can be used for treating heat in blood purple
The diseases such as speckle, purpura, rheumatalgia, traumatic injury, tumor.Consumption and usage: 9-30 gram.
Biological characteristics: Herba Sarcandrae is evergreen undershrub, high 1 ~ 1.5m;Stem is upright, without hair.Joint significantly expands.Leaf to life,
Papery, oval, avette or ovum shape lanceolar, long 6 ~ 17 cm, wide 2 ~ 6 cm, top is tapering, and base portion is narrow or wedge shape, and edge removes
Having rough sawn tooth outside basilar part, increment has a body of gland, and two sides is all without hair;Lateral vein 5 ~ 7 is right, connects from edge camber arch, and petiole length 5 ~
15mm, without hair, base portion symphysis becomes sheath shape;Stipule is caducous.Spending little, Xia Qiu is open, yellow green, without perianth, is gathered into the steady of top life
Locusta or branch form panicle shape;Bract triangle, yellow green, 1 piece of stamen, meat, bar-shaped, flower pesticide 2 Room, and is born in
The both sides on connective top;Gynoecium is made up of, without style 1 lamination.Drupe is spherical, diameter 3 ~ 4mm, shiny red time ripe.
Chemical composition: the chemical composition of antitumor active site has the double Isofraxidin (3,3'-of 3,3'-
Biisofraxidin, 1), pinostrobin (pinostrobin, 2), Isofraxidin (isofraxidin, 3), Palmic acid
(palmitic acid, 4), atractylodes lactone III (atractylenolide III, 5), chloranthalactone E
(chloranthalactone E, 6), Pentadecane acid (pentadecanoic acid, 7), 5-hydroxyl-7,4'-dimethoxy
Flavanone (5-hydroxy-7,4'-dimethoxyflavanone, 8), Yi Si tambulin A (istanbulin A, 9),
2', 4'-dihydroxy-6'-melonia chalcone (uvangoletin, 10), 6,7-dimethoxy coumarin
(scoparone, 11), cupreol (β-sitosterol, 12), daucosterol (daucosterol, 13).Result shows, 1~
7,9~11 have weak effect to suppression growth of tumour cell, and effective site tumor-inhibiting action is relatively strong in vivo, and individualized compound is in vitro
Test performance is not outstanding, shows cytotoxic activity when high dose, traces it to its cause, it may be possible to the compound in effective site
The most collaborative, strengthen antitumor action;Being likely to effective site in vivo is to play antitumor action by non-cytotoxicity approach,
But not can determine that.
Pharmacological action: 1. resisting pathogenic microbes effect.Experiment shows, Herba Sarcandrae has extensive antibacterial action, to golden yellow
Glucose coccus and Resistant strain thereof, will Hayes, Boydii, shigella flexneri, typhoid fever, Salmonella paratyphi, escherichia coli, as pus
Bacillus etc. all have inhibitory action in various degree.Infected by influenza has notable deactivation.2. antitumor action.This group experiment card
Bright, Herba Sarcandrae crude extract, extract, injection etc. all have antitumor activity in various degree.3. immunization.Extract is to cell
The immune indexes such as phagocytic function have facilitation, good immunoloregulation function to be probably one of its antineoplastic action mechanism.
4. anti-ulcer effect.5. promote union of fracture.Additionally, still there is analgesic activity, eliminating phlegm and relieving asthma effect etc..
Toxicological effect: Herba Sarcandrae extractum (1g extractum is equivalent to swollen joint point dry product 10g) is to large and small Mus acute oral female, male
LD50 is all higher than 10g/kg.Belonging to commercial sterility, the nuclear test of mouse inbred strain, bone marrow cells in mice and Salmonella reversion test are
Feminine gender, does not finds mutagenicity.
3. Herba vallisneriae Spiralis: (picria fel-tarrae Lour.), has another name called Radix Picriae felterrae, Radix Picriae felterrae, Herba Houttuyniae, Radix Gentianae, is wide
Western genuine medicinal materials Herba vallisneriae Spiralis Scrophulariaceae Radix Picriae felterrae platymiscium.Belong to traditional herbal medicine.It is mainly distributed on Guangxi, Guangdong, Guizhou and Yunnan etc.
Ground.
Medicinal Materials Characters: be dried vegetation, high 40 ~ 60cm.Stem is polygon, and by undercoat, joint expands, multi-branched.Single leaf to life,
In oval, long 3 ~ 5cm, wide 2 ~ 3cm, yellow green to celadon, the sharp point of tip, often more or less for base portion, prolongs in lower handle, two sides
The most coarse, edge has blunt crenature.Top is raw or axillary-racemes, floral white, lip-like, sepal 4 pieces, outer two pieces relatively big, avette,
Interior two pieces less, bar shaped, feeble QI, bitter in the mouth.
Biological characteristics: Herba vallisneriae Spiralis is grown in the torrid zone, Subtropical hill, under the rainforest in mountain valley or monsoon rainforest, is that a kind of happiness is warm
Moistening, the plant of resistance to the moon.Growing environment requires: average temperature of the whole year is at 20 ~ 22.8 DEG C, and absolute high temperature 40.5 DEG C, the January is average
Temperature more than 12 DEG C.Annual rainfall 135 ~ 1500mm, relative humidity about 80%.It is 40% ~ 50% at shade rate, the loose fertilizer of soil layer
Fertile, moistening, good rich in plant strain growth in the sand of humus.Seed development requires more than 15 DEG C.Tolerance to cold is poor,
In plant division successively in 4 ~ August, bloom, result.Happiness fertilizer, needs large quantity of moisture and nutrient in growth course.Can adopt after planting 5 ~ 6 months
Receive, generally carry out between 9 ~ October.When gathering, medical material is cut together, wash away silt, remove impurity, be spread out under the sun and shine to 6-
Do for 7 one-tenth, continue to shine the most absolutely dry being bundled into again after being bundled into wisp and deposit putting to be dried greatly.
Chemical composition: mainly calabash storehouse element (Cucurbitacin) Triterpenoid and flavone compound, has now been found that
Its effective ingredient is mainly tetracyclic triterpene glycoside and (including: Radix Picriae felterrae aglycon I, picfeltarraenin I A, picfeltarraenin I B, picfeltarraenin
Unit III, picfeltarraenin III, Radix Picriae felterrae aglycon IV, picfeltarraenin IV etc. 12 kinds).Wherein picfeltarraenin I A is Radix Picriae felterrae triterpene position
The composition that middle content is the highest, in dry plant, content is about 0.25%, has central inhibitory action and anticomplementary action, is Herba vallisneriae Spiralis
Main active, is also the main component of quantitative analysis mensuration.With high-performance liquid chromatogram determination, and C18ODS2 post, second is fine-
0.3% phosphoric acid (34:66) is flowing phase, flow velocity 1ml/min, column temperature 25 DEG C, and wavelength is 264nm ].Pharmacological action: pharmacological evaluation is demonstrate,proved
Bright, picfeltarraenin have antiinflammatory action, Detoxication, calmness, ease pain, stable effect, antitumaous effect.
Function with cure mainly: cold in nature, bitter in the mouth, there is the function of heat-clearing and toxic substances removing, reducing swelling and alleviating pain.For cold anemopyretic, swelling throat
Bitterly, the disease such as mumps, gastric heat stomachache, dysentery, traumatic injury, furuncle carbuncle, venom.
Usage and consumption: 9 ~ 15g.It is decocted in water for oral dose.
4. Radix Scrophulariae: for the dry root of goatweed Radix Scrophulariae (Scrophularia ningpoensls Hemsl), begin to carry
In Shennong's Herbal.
Another name: Radix Scrophulariae, black ginseng, wash rice Radix Scrophulariae, crow Radix Scrophulariae, etc..
Biological characteristics: for perennial herb, root is cylindrical, the normal bifurcated in bottom, crust ash yellowish-brown.Stem is upright, four ribs
Shape, smooth or have gland shape pubescence.Leaf is to life;Blade is avette or ovum shape oval, and tip gradually presss from both sides, basal circular or closely carry shape, limit
Edge tool crenation, cyme, in coniform;The long 1-3cm of bennet, inflorescence and bennet have obvious glandular hair;Sepal 5 splits, ovum
Circular;Corolla mulberry, the oblique gyalectiform in pipe portion, there are 5 slivers, stamen 4;Floral disc is obvious;Ovary is upper, Room 2, and style is elongated.Capsule
Oval, the short point of tip, dark green or shallow bottle green, calyx harbors, the month at florescence 7-8, really the phase 8-9 month.
The place of production: the ground such as Zhejiang, Jiangsu, Anhui, Hunan, Guizhou, Shaanxi, cultivates or is born in hillside sylvan life.
Gather: excavate in the Beginning of Winter of around, remove stem, leaf, fibrous root, outwash silt, be exposed to the sun 5-6 days, to time half-dried, pile up 2-3
The internal blackening of angel, then row Exposure to Sunlight, and repeatedly heap, shine for several times, until being completely dried.
Medicinal Materials Characters: this product is that class is cylindrical, and centre is the thickest or upper coarse and lower fine, the micro-change song having, long 6-20cm, diameter 1-
3cm, surface lark or taupe, there is irregular longitudinal furrow, hole skin sample projection of growing crosswise and sparse transverse crack and mark of fibrous root.Matter
Solid, it is not easily broken, section black, micro-glossy.Gas is special like caramel, bitter in the mouth, micro-hardship.
Nature and flavor with return through: sweet, bitter, salty, be slightly cold.Return lung, stomach, kidney channel.
Function with cure mainly: removing heat from blood YIN nourishing, eliminating fire and detoxication.Hinder for consumption of YIN caused by febrile disease, tongue cutting edge of a knife or a sword excessive thirst, maculae caused by violent heat pathogen, Tianjin constipation,
Hectic fever due to YIN-deficiency chronic cough, conjunctival congestion, pharyngalgia, scrofula, Bai Shun, carbuncle disease poison etc..
Usage and consumption: 9-15g.
Note: should not be with Rhizoma et radix veratri (Radix Rhizoma Veratri) with using.
Chemical composition:
Radix Scrophulariae mainly containing iridoids, Phenylpropanoid Glycosides glycoside, still containing plant sterol, organic acid, flavonoid, triterpene soap
Glycosides, performance oil, saccharide, alkaloid, the monoterpene of trace, Diterpene etc..Wherein filter out 6 kinds with mtt assay and there is antitumor work
Property with compound in phenolic hydroxyl group number have substantial connection.With the extract of dichloromethane and ethyl acetate extract people multiple
Cancerous cell has cytotoxicity, and the material wherein with the strongest active anticancer has: oleanonic acid derivant and ursodeoxycholic
Acid derivative, all has good inhibiting effect to breast carcinoma, leukemia, skin carcinoma, pulmonary carcinoma etc..The formation of blood vessel can make cancer thin
Born of the same parents' growth rate is that Logarithmic degree is accelerated, and research finds, the activity of the water extract suppression angiogenesis of Radix Scrophulariae is the most prominent, it may be possible to profound
One of effective way of ginseng antitumor action.Effective ingredient Phenylpropanoid Glycosides glycosides has good anti-oxidation protection and makees hereditary material
With, thus stablize hereditary material, reduce its mutation rate, it is also possible to one of approach of Radix Scrophulariae antitumaous effect.
Pharmacological action:
1. pair neural effect.(1). protection nerve;(2). antidepressant;(3). improve memory;2. antiinflammatory, antioxygen
Change effect;3. the liver protecting;4. anticoagulation;5. antitumor;6. enhancing immunity;7. gout;8. resist myocardial ischemia;The most anti-brain
Ischemia;10. anti-diabetic;11. antibacterial actions.
Toxicological effect: toxicity is low, few side effects.
The production method of described oral liquid:
(1) medicine is claimed: take in leaf containing pearl, Herba Sarcandrae, Herba vallisneriae Spiralis, Radix Scrophulariae by above parts by weight.
(2) water extraction: above Chinese medicine adds 10-15 times amount water heated and boiled 1-2 hour in putting Chinese medicine extracting tank, releases medicine
Liquid, filters, and medicinal residues add 5-10 times of water and add thermogravimetric and boil 0.5-1 hour, and medicinal residues are released, filtering liquid medicine.
(3) concentration of liquid medicine: in medicinal liquid puts concentration tank, heating is concentrated into 2-3 times of medicine volume, cooling.
(4) ethanol precipitation: above medicinal liquid adds volumetric concentration 95% ethanol and reaches 60-70% to concentration of alcohol, is put in 4 after stirring
DEG C-8 DEG C stand 12-24 hour, filter to get filtrate.
(5) reclaim ethanol: above medicinal liquid puts heating recovery ethanol in ethanol recycling can, release medicinal liquid, cooling, filter medicine
Liquid.
(6) concentration of liquid medicine: above filtrate is heated to 80 DEG C of cream being concentrated to give relative density 1.10-1.15 in putting concentration tank
Shape medicine.
(7) oral liquid preparation: above cream drug adds the pure water of 5-6 times, then adds the sucrose syrup of overall volume 20%
Make oral liquid, quantitatively, fill, sealing, sterilizing, pack to obtain finished product.
The production method of described capsule:
(1) medicine is claimed: take in leaf containing pearl, Herba Sarcandrae, Herba vallisneriae Spiralis, Radix Scrophulariae by above parts by weight.
(2) water extraction: above Chinese medicine adds 10-15 times amount water heated and boiled 1-2 hour in putting Chinese medicine extracting tank, releases medicine
Liquid, filters, and medicinal residues add 5-10 times of water and add thermogravimetric and boil 0.5-1 hour, and medicinal residues are released, filtering liquid medicine.
(3) concentration of liquid medicine: in medicinal liquid puts concentration tank, heating is concentrated into 2-3 times of medicine volume, cooling.
(4) ethanol precipitation: above medicinal liquid adds volumetric concentration 95% ethanol and reaches 60-70% to concentration of alcohol, is put in 4 after stirring
DEG C-8 DEG C stand 12-24 hour, filter to get filtrate.
(5) reclaim ethanol: above medicinal liquid puts heating recovery ethanol in ethanol recycling can, release medicinal liquid, cooling, filter medicine
Liquid.
(6) concentration of liquid medicine: above filtrate is heated to 80 DEG C of cream being concentrated to give relative density 1.10-1.15 in putting concentration tank
Shape medicine.
(7) pharmacy powder: above cream drug adds adjuvant, powder process is dried to obtain medicated powder.
(8) glue capsule and encapsulation: above medicated powder capsule machine makes capsule, encapsulates to obtain capsule finished product.
The production method of described tablet:
(1) medicine is claimed: take Herba Sarcandrae by weight.
(2) ethanol extraction: put by Herba Sarcandrae in reflux, extract, pot, adds volumetric concentration 95% ethanol 5-10 times, is heated to reflux 1-
2 hours, filtering liquid medicine, medicinal residues added volumetric concentration 50% ethanol 3-7 times, and second time is heated to reflux 1-1.5 hour, releases medicinal liquid mistake
Filter to obtain filtrate a.
(3) water extraction: take by above parts by weight and put decoct medicinal herbs containing pearl, Radix Scrophulariae and above (2) remaining medicinal residues in Herba vallisneriae Spiralis, leaf
In pot, adding water 10-15 times to heat and boil 1-2 hour, release medicinal liquid, filter, medicinal residues add water 5-10 times, and adding thermogravimetric, to boil 0.5-1 little
Time, release medicinal liquid, filter to obtain medicinal liquid.
(4) concentration of liquid medicine: in above (3) medicinal liquid puts concentration pan, heating is concentrated into 2-3 times of volume of medicine, cooling.
(5) ethanol precipitation: above (4th) step concentrated medicament adds volumetric concentration 95% ethanol and reaches 60-70% to concentration of alcohol, stirs
Putting 4 DEG C-8 DEG C after mixing and stand 12-24 hour, filter to get filtrate b.
(6) reclaim ethanol: by 2-in-1 also for above (2nd) step filtrate 1 and (5th) step filtrate, put in ethanol reclaims pot and heat back
Receive ethanol, release medicinal liquid, cooling, filter to obtain medicinal liquid.
(7) concentration of liquid medicine: in (6th) step gained medicinal liquid puts concentration pan, heating is concentrated to give paste.
(8) pharmacy powder: above paste adds adjuvant, powder process is dried to obtain medicated powder.
(9) film-making: above medicated powder adds right amount of auxiliary materials, mixing, pelletizes, and is dried, and tabletting, bag sheet, coating, subpackage obtains sheet
Agent.
The production method of described granule:
(1) medicine is claimed: weigh Herba Sarcandrae by weight;
(2) ethanol extraction: put by Herba Sarcandrae in reflux, extract, pot, adds volumetric concentration 95% ethanol 5-10 times, is heated to reflux 1-
2 hours, filtering liquid medicine, medicinal residues added volumetric concentration 50% ethanol 3-7 times, and second time is heated to reflux 1-1.5 hour, releases medicinal liquid mistake
Filter to obtain filtrate a;
(3) water extraction: take by above parts by weight and put decoct medicinal herbs containing pearl, Radix Scrophulariae and (2nd) the remaining medicinal residues of step in Herba vallisneriae Spiralis, leaf
In pot, adding water 10-15 times to heat and boil 1-2 hour, release medicinal liquid, filter, medicinal residues add water 5-10 times, and adding thermogravimetric, to boil 0.5-1 little
Time, release medicinal liquid, filter to obtain medicinal liquid;
(4) concentration of liquid medicine: in above (3rd) step medicinal liquid puts concentration pan, heating is concentrated into 2-3 times of volume of medicine, cooling;
(5) ethanol precipitation: above (4th) step concentrated medicament adds volumetric concentration 95% ethanol and reaches 60-70% to concentration of alcohol, stirs
Putting 4 DEG C-8 DEG C after mixing and stand 12-24 hour, filter to get filtrate b;
(6) reclaim ethanol: by 2-in-1 also for above (2nd) step filtrate 1 and (5th) step filtrate, put in ethanol reclaims pot and heat back
Receive ethanol, release medicinal liquid, cooling, filter to obtain medicinal liquid;
(7) concentration of liquid medicine: in (6th) step gained medicinal liquid puts concentration pan, heating is concentrated to give paste;
(8) pharmacy powder: above paste is with sucrose by 2 times of mixing of crude drug total amount, and powder process is dried to obtain medicated powder;Use granulator
Pelletize, quantitatively, encapsulate to obtain finished product.
Described adjuvant includes: including filler, disintegrating agent, lubricant, coating materials etc., filler is starch, dextrin, carboxylic first
Base starch, calcium hydrogen phosphate, Starch 1500 and other pharmaceutic adjuvants;Disintegrating agent be sodium carboxymethyl cellulose, hydroxypropyl cellulose, Starch 1500,
The kind pharmaceutic adjuvant flowed and there is water swelling;Lubricant is Polyethylene Glycol, magnesium stearate, Pulvis Talci and has lubrication
Pharmaceutic adjuvant;Coating materials is Opadry 11 type, Opadry Chinese medicine, Opadry tm type, (hydroxypropyl methyl cellulose gathers in U.S. many shows
Compound), ethyl cellulose (IDALL's show), refined gram suitable (water-borne acrylic type enteric coating system) etc..
The invention has the beneficial effects as follows:
The present invention has by theory of Chinese medical science activating blood flow and removing blood stasis, effect of dispelling wind and removing obstruction in the collateral, dispel that blood stasis in liver, poison be poly-, the stagnation of QI,
Recovering healthy energy, have preferable anticancer cancer inhibitor cell effect, the anticancer cancer result of the test that presses down of this laboratory shows, to hepatoma carcinoma cell
Strain growth has obvious inhibitory action, and compound preparation becomes apparent from than single pharmaceutical preparation, embodies its synergism;Medicine is by pressing down
Cancerous cell telomerase activation processed, makes cancerous cell telomeric dna replicate and slows down and be gradually shortened, and growth of cancer cells slows down, and is eventually striking to
Apoptosis, this is the mechanism of this medicine effect;Therapeutic efficacy for hepatic carcinoma be observation indicate that by clinical trial, the obvious pain relief of curative effect, swollen
Block expansion slows down, and extends longest-lived and reaches 16 years, belongs to cancerous cell poison, and several drugs compatibility curative effect is aobvious to be increased, except there being hepatocarcinoma
Outside effect, the most effective in cure to gastric cancer test and the kinds cancer such as pulmonary carcinoma, lymphatic cancer, but little to normal cytotoxicity (several avirulence),
And conventional anticarcinogen toxicity is big, infringement normal cell, this Chinese medicine compound has prominent advantage and progress.Therefore recurrence due to taking drug in this
Side have obvious cancer suppressing action, safety non-toxic, can take for a long time, the advantage such as medicine source is abundant.
Accompanying drawing explanation
Fig. 1 is table 1 (1) group (adding compound recipe) hepG2 hepatoma carcinoma cell detection figure in above 1.1 inhibition of cancer cell tests.
Fig. 2 is table 1 (2) group (Jia Yeli contains pearl) hepatoma carcinoma cell detection figure in above 1.1 inhibition of cancer cell tests.
Fig. 3 is table 1 (3) group (adding Folium et Ramulus Cephalotaxi) hepatoma carcinoma cell detection figure in above 1.1 inhibition of cancer cell tests.
Fig. 4 is table 1 (4) group (not adding) hepG2 hepatoma carcinoma cell detection figure in above 1.1 inhibition of cancer cell tests.
Fig. 5 is hepG2 hepatoma carcinoma cell detection figure (matched group) of non-dosing.
Fig. 6 is the hepG2 hepatoma carcinoma cell detection figure before dosing.
Fig. 7 is to add hepG2 hepatoma carcinoma cell detection figure after compound anti-cancer medicine.
Fig. 8 is to add hepG2 hepatoma carcinoma cell detection figure after compound anti-cancer medicine.
Fig. 9 is the hepG2 hepatoma carcinoma cell detection figure of non-dosing.
Detailed description of the invention
Embodiment of the invention below:
Embodiment 1:
Weigh in leaf containing 6 kilograms of pearl, Herba Sarcandrae 9 kilograms, Herba vallisneriae Spiralis 8 kilograms, Radix Scrophulariae 9 kilograms.Above-mentioned Chinese medicine → put Chinese medicine carries
In taking tank → add 10-15 times of water → heated and boiled 1-2 hour → releasing medicinal liquid → medicinal residues and add 5-10 times amount water again, reheating is boiled
05.-1 hour, medicinal liquid was released, and filters, merges twice medicinal liquid, put by medicinal liquid in concentration tank, and heating is concentrated into 2-3 times of medicine volume,
Cooling.Then medicinal liquid adds volumetric concentration 95% ethanol of 3 times amount and reaches 60-70% to concentration of alcohol, puts 4 DEG C-8 DEG C, stand after stirring
12-24 hour, filter;Filtrate heating recovery ethanol, obtains medicinal liquid, filters, put in concentration pan after cooling, heating is concentrated into paste.
With sucrose 4 kilograms the syrup of 80% (the most heated turn to), add pure water to cumulative volume 2000ml, hybrid filtering post package, often
Prop up (bottle) 10ml.Sterilization.Pack to obtain finished product.Consumption: adult can be each serving 10ml, oral 2-3 time.
Embodiment 2:
Weigh in leaf containing 15 kilograms of pearl, Herba Sarcandrae 30 kilograms, Herba vallisneriae Spiralis 15 kilograms, Radix Scrophulariae 10 kilograms.In said medicine → put
In medicine extraction pot → and adding the 10-15 times of water yield → heated and boiled 1-2 hour → releasing medicinal liquid, medicinal residues add 5-10 times amount water → heavily boil again
Boil 0.5-1 hour → releasing medicinal residues.Above twice medicinal liquid mixing → filtration → medicinal liquid is put in concentration pan, and heating is concentrated into 2-3 times
Medicine volume, cooling.Then medicinal liquid adds 3-4 times of volume volumetric concentration 95% ethanol and reaches 60-70% to concentration of alcohol, puts 4 after stirring
DEG C-8 DEG C, stand 12-24 hour, filter;Filtrate is put in ethanol recycling can, reclaims ethanol, gained medicinal liquid after cooling, filters, put
In concentration pan, heating concentrates, to paste.With sucrose 4-6 kilogram the syrup of 80% (the most heated turn to), add pure water and be diluted to
Oral liquid, constant volume, making oral liquid sugar content is 20%(weight: volume ratio), filter, fill, sealing.Sterilization.After packaging
Finished product.
Embodiment 3:
Ye Li contains 15 kilograms of pearl, Herba Sarcandrae 15 kilograms, Herba vallisneriae Spiralis 12 kilograms, Radix Scrophulariae 12 kilograms.Above Chinese medicine, puts Chinese medicine extraction
In tank → and adding 10-15 times of dose water → heated and boiled 1-2 hour → releasing medicinal liquid, medicinal residues add 5-10 times amount water → heavily boil again
05.-1 hour → release medicinal liquid, above twice medicinal liquid merged, and in filtration → medicinal liquid puts concentration pan, heating concentrates, to 2-3 times of medicine body
Long-pending, cooling.Then add 3-4 times amount volumetric concentration 95% ethanol and reach 60-70% to concentration of alcohol, after stirring, put 4 DEG C-8 DEG C, stand
12-24 hour, filter;Filtrate puts heating recovery ethanol in alcohol recovery device, and medicinal liquid is released, and cooling is filtered, and medicinal liquid puts concentration
In pot, heating is concentrated into paste.Add adjuvant, make medicated powder, on capsule machine on glue capsule → sealing/pouring apparatus encapsulate → capsule finished product.
Embodiment 4:
Ye Li contains 15 kilograms of pearl, Herba Sarcandrae 9 kilograms, Herba vallisneriae Spiralis 8 kilograms, Radix Scrophulariae 15 kilograms.Above-mentioned Chinese medicine Herba Sarcandrae is first put into
Ethanol extraction in alcohol reflux tank → add volumetric concentration 95% ethanol 5-10 times amount → be heated to reflux 1-2 hour → release medicinal liquid, mistake
In filter → tank, medicinal residues add 3-7 times → twice medicinal liquid of volumetric concentration 50% ethanol again and merge (medicinal liquid containing ethanol);Medicinal residues are with other
Chinese medicine Radix Picriae felterrae, Herba Andrographis together, are put in Chinese medicine extracting tank → 10-15 times → heated and boiled 1-2 hour that adds water → releasing medicine
Liquid (filtration) → medicinal residues add water 5-10 times → reheat boil 0.5-1 hour → release medicinal liquid (filtration) → the conjunction of twice medicinal liquid
And → put heating in concentration pan concentrate → to dose 2-3 times → cooling → stirring, put 4 DEG C-8 DEG C, stand 12-24 hour → filtration
→ filtrate merge with above twice medicinal liquid Han ethanol → reclaim ethanol → medicinal liquid cool down → filter → put concentration pan in heating concentrate
→ it is dried → goes up machine tabletting → upper machine coating → subpackage to paste → add adjuvant → powder process, obtain tablet.
Embodiment 5:
Ye Li contains 10 kilograms of pearl, Herba Sarcandrae 15 kilograms, Herba vallisneriae Spiralis 8 kilograms, Radix Scrophulariae 15 kilograms.Above-mentioned Chinese medicine Herba Sarcandrae is first put into
Ethanol extraction in alcohol reflux tank → add volumetric concentration 95% ethanol 5-10 times amount → be heated to reflux 1-2 hour → release medicinal liquid, mistake
In filter → tank, medicinal residues add 3-7 times → twice medicinal liquid of volumetric concentration 50% ethanol again and merge (medicinal liquid containing ethanol);Medicinal residues are with other
Chinese medicine Radix Picriae felterrae, Herba Andrographis together, are put in Chinese medicine extracting tank → 10-15 times → heated and boiled 1-2 hour that adds water → releasing medicine
Liquid (filtration) → medicinal residues add water 5-10 times → reheat boil 0.5-1 hour → release medicinal liquid (filtration) → the conjunction of twice medicinal liquid
And → put heating in concentration pan concentrate → to dose 2-3 times → cooling → stirring, put 4 DEG C-8 DEG C, stand 12-24 hour → filtration
→ filtrate merge with above twice medicinal liquid Han ethanol → reclaim ethanol → medicinal liquid cool down → filter → put concentration pan in heating concentrate
→ to paste → with sucrose by 2 times of mixing of crude drug total amount → be dried medicated powder → with granulator pelletize → quantitatively → encapsulate
Granule finished product.
Described in above example, adjuvant includes: filler, disintegrating agent, lubricant, coating materials etc., filler is starch, paste
Essence, carboxymethyl starch, calcium hydrogen phosphate, Starch 1500 and other pharmaceutic adjuvants;Disintegrating agent is sodium carboxymethyl cellulose, hydroxy propyl cellulose
Element, Starch 1500, the kind pharmaceutic adjuvant flowed and there is water swelling;Lubricant is Polyethylene Glycol, magnesium stearate, Pulvis Talci and has
The pharmaceutic adjuvant of lubrication;Coating materials is Opadry 11 type, Opadry Chinese medicine, Opadry tm type, U.S. many elegant (hydroxypropyl methyls
Cellulosic polymer), ethyl cellulose (IDALL's show), refined gram suitable (water-borne acrylic type enteric coating system) etc..
The following is experimentation and clinical research data: 1. experimentation data:
1.1 inhibition of cancer cell tests.With 1640 culture medium culturing hepatoma carcinoma cell (Hepg2) be separately added into different anticancer in
Medicine is cultivated together, and (1) is organized as adding this compound extract (anticancer No. 1), and (2) group is Jia Yeli (anticancer No. 2) Han pearl extracting solution,
(3) group is for adding tricuspid shirt extracting solution, and (4) are organized as compareing not dosing.The cell number statistical result of each group.Result shows, matched group (4)
Cell number is most, is followed successively by thereafter (3), (2), (1) group.It is shown in Table 1
Table 1 is respectively organized cell number and is compared
Variance analysis: compare with (4) group△P < 0.05,△△P < 0.01, compares with (3) group,*P < 0.05, with (2) group ratio
Relatively,▲▲P < 0.01.
Each group cellular morphology change after 1.2 medications.Result shows, (4) group is adherent for blank group hepatoma carcinoma cell, is not added with
Medicine, shows hepatic cell growth speed in photograph, cell is polygon, has pseudopodium, subregion to occur that cladding grows, density
Greatly, cell is bright, and granule is few, without peeling phenomenon, sees Fig. 4;(1) group is compound recipe (anticancer No. 1) group, and liver cancer cell growth is all subject to
Suppression, cell enlargement, gradually become round, pseudopodium reduces, and iuntercellular is away from increase, and along with the increase of medicine, local cells comes off substantially,
Bottle end vacancy, density is little, and intracellular granular is many, coarse, shows aging, sees Fig. 1;(2) group, (3) group are respectively the most anticancer No. 2 and three
Point China fir group also occurs organizing similar phenomenon to (1), but the display of (three) group is lighter.
The 1.3 anticancer compound recipes inhibition test to hepatocellular carcinoma H22 cell proliferation. it is thin that variable concentrations compound recipe acts on hepatocarcinoma
After born of the same parents 24h, A value all declines, compound recipe concentration the highest A value the lowest (F=174.130, P=0.000);Hepatoma cell proliferation is had aobvious
Write inhibitory action, the highest (X of the highest suppression ratio of concentration2=48.971, P=0.000).It is shown in Table 2.
Table 2 variable concentrations compound recipe group and matched group hepatoma carcinoma cell HepG2A value, suppression ratio compares
Variance analysis: A value, compares with blank group*P < 0.05, respectively organizes suppression ratio, compares with blank group,△P
< 0.01.
1.4 the impact that anticancer compound recipe is on hepatoma carcinoma cell telomerase activation. compare with blank group, in compound recipe, leaf containing pearl,
Folium et Ramulus Cephalotaxi group all can suppress hepatoma carcinoma cell telomerase activation (F=7.942, P=0.010), three groups of anticarcinogen differences of inhibitory action
Not statistically significant (P > 0.05). show that medicine passes through anticancer telomerase activation, make cancerous cell telomeric dna replicate and slow down
And be gradually shortened, growth of cancer cells slows down, and is eventually striking to apoptosis, and this is the mechanism of this medicine effect. it is shown in Table 3.
Each group of table 3 is to hepatoma carcinoma cell HepG2The comparison of telomerase activation
Variance analysis: compare with blank group*P < 0.05,△P < 0.05.
2. clinical research data:
This formula began one's study from nineteen eighty-two, observes and treats liver cancer patient, and clinical statistics patient 20 example is evident in efficacy, always
Effective percentage is 68.8%, the longest 16 years life-spans of prolongation.(clinical case and formula were not delivered on magazine). model case:
Clinical case 1:
Patient Zhu, this city epidemic prevention station doctor.Nineteen eighty-two is diagnosed as constitutional in The People's Hospital, Guangxi Zhuang Autonomous Region
Hepatocarcinoma.Entire patient's edema sees medical expert's consultation, checks liver enlargement, hard, rough surface, through chemical examination, rocket electrophoresis, alpha-fetoprotein
Mensuration, B ultrasonic, biopsy etc. check, being diagnosed as primary hepatocarcinoma, receipts are hospitalized for treatment.Adhere to being reluctant to stay in Nanning by patient
Doctor is in hospital, and unit sends ambulance to take back original place treatment.Medicinal: compound anti-cancer 1 is (containing pearl 6g, Herba Pileae Scriptae 10g, Herba vallisneriae Spiralis in leaf
10g, Radix Scrophulariae 9g), be decocted in water for oral dose, every day potion;After this medicine is done piece agent, each 3-4 sheet, every day 2-3 time.Long-term taking.Fixed
Phase is to Nanning autonomous region hospital, the check of hospital of city.Review result, hepatic neoplasms has no expansion, does not also reduce, also without transfer disease
Stove, can the basic controlling state of an illness.Daily life can be taken care of oneself, and due to illness early retirement is in rest.The end of the year 1997, because catching a cold into local county
Hospitalize, penicillin anaphylaxis causes anuria, fecal incontinence, dyspnea, heart failure, stupor, escape danger after swinging and rescuing, and Hou Zhuan city cures
Institute's oncology continual cure, the state of an illness is the most stable, checks: X-ray and CT sheet check that hepatic neoplasms exists, and has no expansion and turns
Moving, chemical examination liver function is normal, but is associated with chronic constrictive pericarditis, and calcification, it is impossible to carry out operative treatment, the heart
Decline.After being admitted to hospital about one month, the state of an illness is more stable, during just meeting the Spring Festival, it is desirable to leave hospital, but continues medication treatment.Leave hospital about two
Many months, heart failure, dyspnea not yet solved, and the rear state of an illness increases the weight of the most suddenly, back into Affiliated Hospital's surgical intervention, after a few days
Turning again internal medicine, after one week, because of heart failure, that all rescue measures proved ineffectual is dead.The course of disease is made a definite diagnosis hepatocarcinoma from first half of the year nineteen eighty-two and is gone to the first half of the year in 1998
Generation, terminal hour 65 years old.
Clinical case 2:
Li Linguo, man, 45 years old, Bose City factory worker, within 1998, December was diagnosed as constitutional in Bose City hospital on 10th
Hepatocarcinoma is admitted to hospital hospitalization, and the state of an illness deteriorates rapidly seriously, ascites, abdominal distention occurred, it is impossible to walking of leaving the bed, and is unable to leave the bed.In
On January 5th, 1999 takes No. 1 mixture of compound anti-cancer, every day 1 bottle (100ml), takes in three times.Treat one the course for the treatment of (two stars
Phase).Controlling the rear state of an illness to be clearly better, walking of can leaving the bed voluntarily, take a walk in city, spirit, appetite the most all take a favorable turn, and cure from city farthest
Institute is feasible goes to about 2 km steps, and the state of an illness relatively stably is left hospital to be in and recuperated.To in May, 1999, it is in and crosses play motion because of unexpected
Cause esophageal vein Rupture haemorrhag, the invalid death of first aid.
Clinical case 3:
Huang, man, the ground large hospital treatments such as 40 years old, nineteen ninety suffered from oral cancer, once arrived Nanning, Guangzhou, due to diffusingsurface
Long-pending excessive, cannot operative treatment, take this medicine and carry out conservative treatment, cancerous protuberance is obviously reduced, for the several years.
Claims (7)
1. the compound Chinese medicinal preparation treating hepatocarcinoma, it is characterised in that: its effective ingredient is by the Chinese medicine of following parts by weight
Raw material is made:
Ye Li 5-15 part on pearl;
Herba Sarcandrae 5-30 part;
Herba vallisneriae Spiralis 5-15 part;
Radix Scrophulariae 5-15 part;
Described compound Chinese medicinal preparation is oral liquid, capsule, tablet, granule or other peroral dosage form.
The compound Chinese medicinal preparation for the treatment of hepatocarcinoma the most according to claim 1, it is characterised in that: the production method of oral liquid is such as
Under:
(1) medicine is claimed: weigh by weight in leaf containing pearl, Herba Sarcandrae, Herba vallisneriae Spiralis and Radix Scrophulariae;
(2) water extraction: add 10-15 times amount water heated and boiled 1-2 hour in Chinese medicine is put Chinese medicine extracting tank, releases medicinal liquid, filters,
Medicinal residues add 5-10 times of water and add thermogravimetric and boil 0.5-1 hour, and medicinal residues are released, filtering liquid medicine;
(3) concentration of liquid medicine: in medicinal liquid puts concentration tank, heating is concentrated into 2-3 times of medicine volume, cooling;
(4) ethanol precipitation: above medicinal liquid adds volumetric concentration 95% ethanol and reaches 60-70% to concentration of alcohol, is put in 4 DEG C-8 DEG C after stirring
Stand 12-24 hour, filter to get filtrate;
(5) reclaim ethanol: above medicinal liquid puts heating recovery ethanol in ethanol recycling can, release medicinal liquid, cooling, filtering liquid medicine;
(6) concentration of liquid medicine: above filtrate is heated to 80 DEG C of poultices being concentrated to give relative density 1.10-1.15 in putting concentration tank
Thing;
(7) oral liquid preparation: above cream drug adds the pure water of 5-6 times, then the sucrose syrup adding overall volume 20% is made
Oral liquid, quantitatively, fill, sealing, sterilizing, pack to obtain finished product.
The compound Chinese medicinal preparation for the treatment of hepatocarcinoma the most according to claim 1, it is characterised in that: the production method of capsule is such as
Under:
(1) medicine is claimed: weigh by weight in leaf containing pearl, Herba Sarcandrae, Herba vallisneriae Spiralis and Radix Scrophulariae;
(2) water extraction: add 10-15 times amount water heated and boiled 1-2 hour in Chinese medicine is put Chinese medicine extracting tank, releases medicinal liquid, filters,
Medicinal residues add 5-10 times of water and add thermogravimetric and boil 0.5-1 hour, and medicinal residues are released, filtering liquid medicine;
(3) concentration of liquid medicine: in medicinal liquid puts concentration tank, heating is concentrated into 2-3 times of medicine volume, cooling;
(4) ethanol precipitation: above medicinal liquid adds volumetric concentration 95% ethanol and reaches 60-70% to concentration of alcohol, is put in 4 DEG C-8 DEG C after stirring
Stand 12-24 hour, filter to get filtrate;
(5) reclaim ethanol: above medicinal liquid puts heating recovery ethanol in ethanol recycling can, release medicinal liquid, cooling, filtering liquid medicine;
(6) concentration of liquid medicine: above filtrate is heated to 80 DEG C of poultices being concentrated to give relative density 1.10-1.15 in putting concentration tank
Thing;
(7) pharmacy powder: above cream drug adds adjuvant, powder process is dried to obtain medicated powder;
(8) glue capsule and encapsulation: above medicated powder capsule machine makes capsule, encapsulates to obtain capsule finished product.
The compound Chinese medicinal preparation for the treatment of hepatocarcinoma the most according to claim 1, it is characterised in that: the production method of tablet is such as
Under:
(1) medicine is claimed: weigh Herba Sarcandrae by weight;
(2) ethanol extraction: put by Herba Sarcandrae in reflux, extract, pot, adds volumetric concentration 95% ethanol 5-10 times, is heated to reflux 1-2 little
Time, filtering liquid medicine, medicinal residues add volumetric concentration 50% ethanol 3-7 times, and second time is heated to reflux 1-1.5 hour, release medical filtration and obtain
Filtrate a;
(3) water extraction: take by above parts by weight and put medicine boiler containing pearl, Radix Scrophulariae and (2nd) the remaining medicinal residues of step in Herba vallisneriae Spiralis, leaf
In, adding water 10-15 times to heat and boil 1-2 hour, release medicinal liquid, filter, medicinal residues add water 5-10 times, add thermogravimetric and boil 0.5-1 hour,
Release medicinal liquid, filter to obtain medicinal liquid;
(4) concentration of liquid medicine: in above (3rd) step medicinal liquid puts concentration pan, heating is concentrated into 2-3 times of volume of medicine, cooling;
(5) ethanol precipitation: above (4th) step concentrated medicament adds volumetric concentration 95% ethanol to concentration of alcohol and reaches 60-70%, after stirring
Putting 4 DEG C-8 DEG C and stand 12-24 hour, filter to get filtrate b;
(6) reclaim ethanol: merged by above (2nd) step filtrate a and (5th) step filtrate b, put ethanol and reclaim heating recovery second in pot
Alcohol, releases medicinal liquid, cooling, filters to obtain medicinal liquid;
(7) concentration of liquid medicine: in (6th) step gained medicinal liquid puts concentration pan, heating is concentrated to give paste;
(8) pharmacy powder: above paste adds adjuvant, powder process is dried to obtain medicated powder;
(9) film-making: above medicated powder adds right amount of auxiliary materials, mixing, pelletizes, and is dried, and tabletting, bag sheet, coating, subpackage obtains tablet.
The compound Chinese medicinal preparation for the treatment of hepatocarcinoma the most according to claim 1, it is characterised in that: the production method of granule is such as
Under:
(1) medicine is claimed: weigh Herba Sarcandrae by weight;
(2) ethanol extraction: put by Herba Sarcandrae in reflux, extract, pot, adds volumetric concentration 95% ethanol 5-10 times, is heated to reflux 1-2 little
Time, filtering liquid medicine, medicinal residues add volumetric concentration 50% ethanol 3-7 times, and second time is heated to reflux 1-1.5 hour, release medical filtration and obtain
Filtrate a;
(3) water extraction: take by above parts by weight and put medicine boiler containing pearl, Radix Scrophulariae and (2nd) the remaining medicinal residues of step in Herba vallisneriae Spiralis, leaf
In, adding water 10-15 times to heat and boil 1-2 hour, release medicinal liquid, filter, medicinal residues add water 5-10 times, add thermogravimetric and boil 0.5-1 hour,
Release medicinal liquid, filter to obtain medicinal liquid;
(4) concentration of liquid medicine: in above (3rd) step medicinal liquid puts concentration pan, heating is concentrated into 2-3 times of volume of medicine, cooling;
(5) ethanol precipitation: above (4th) step concentrated medicament adds volumetric concentration 95% ethanol to concentration of alcohol and reaches 60-70%, after stirring
Putting 4 DEG C-8 DEG C and stand 12-24 hour, filter to get filtrate b;
(6) reclaim ethanol: merged by above (2nd) step filtrate a and (5th) step filtrate b, put ethanol and reclaim heating recovery second in pot
Alcohol, releases medicinal liquid, cooling, filters to obtain medicinal liquid;
(7) concentration of liquid medicine: in (6th) step gained medicinal liquid puts concentration pan, heating is concentrated to give paste;
(8) pharmacy powder: above paste is with sucrose by 2 times of mixing of crude drug total amount, and powder process is dried to obtain medicated powder;By the mechanism of pelletizing
Grain, quantitatively, encapsulates to obtain finished product.
6. according to the compound Chinese medicinal preparation of the treatment hepatocarcinoma described in claim 3 or 4, it is characterised in that: described adjuvant includes: fill out
Filling agent, disintegrating agent, lubricant and coating materials, described filler is starch, dextrin, carboxymethyl starch, calcium hydrogen phosphate or Starch 1500;
Described disintegrating agent is sodium carboxymethyl cellulose, hydroxypropyl cellulose, Starch 1500 or kind stream;Described lubricant is Polyethylene Glycol, tristearin
Acid magnesium or Pulvis Talci;Described coating materials be Opadry 11 type, Opadry Chinese medicine, Opadry tm type, hydroxypropyl methyl cellulose gather
Compound or ethyl cellulose.
The compound Chinese medicinal preparation for the treatment of hepatocarcinoma the most according to claim 1 answering in terms of the medicine of preparation treatment hepatocarcinoma
With.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410147463.0A CN103948736B (en) | 2014-04-14 | 2014-04-14 | The compound Chinese medicinal preparation for the treatment of hepatocarcinoma and production method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410147463.0A CN103948736B (en) | 2014-04-14 | 2014-04-14 | The compound Chinese medicinal preparation for the treatment of hepatocarcinoma and production method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103948736A CN103948736A (en) | 2014-07-30 |
CN103948736B true CN103948736B (en) | 2016-10-12 |
Family
ID=51326177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410147463.0A Active CN103948736B (en) | 2014-04-14 | 2014-04-14 | The compound Chinese medicinal preparation for the treatment of hepatocarcinoma and production method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103948736B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111991474A (en) * | 2020-09-07 | 2020-11-27 | 深圳市桦健量子生物科技有限公司 | Lucid ganoderma oral liquid and preparation method thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1435248A (en) * | 2003-02-28 | 2003-08-13 | 广西万通制药有限公司 | Chinese medicine preparation for treating upper respiratory system diseases, skin infection and pile, and preparing method thereof |
CN1546090A (en) * | 2003-12-10 | 2004-11-17 | �Ϻ��ٿ�ҩҵ����˾ | Anticancer Chinese traditional medicine preparation and preparation process and application thereof |
CN1954838B (en) * | 2005-10-26 | 2010-05-12 | 山东轩竹医药科技有限公司 | Medical composite of antineoplastic |
CN103285343B (en) * | 2013-04-17 | 2015-04-01 | 山东省立医院 | Medicine for treating liver cancer and preparation method thereof |
CN103463554B (en) * | 2013-04-26 | 2015-07-29 | 上海中医药大学 | A kind of treat malignant tumor pharmaceutical composition and preparation method and purposes |
-
2014
- 2014-04-14 CN CN201410147463.0A patent/CN103948736B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN103948736A (en) | 2014-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101972338B (en) | Chinese medicinal preparation for treating infantile upper respiratory tract infection and preparation method thereof | |
CN102302673B (en) | Traditional Chinese medicine compound preparation for preventing and treating diabetic nephropathy (DN) | |
CN102247479B (en) | Antitumor strong medicine and preparation method thereof | |
CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
CN103301267A (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
CN103041256A (en) | Chinese herb preparation for curing recurrent respiratory tract infection of children | |
CN103349693A (en) | Preparation and using method of pure Chinese herbal medicine composition for treating allergic rhinitis | |
CN106215118A (en) | Antineoplastic health preparation and preparation method thereof | |
CN103041257A (en) | Chinese materia medica preparation for curing high fever and respiratory tract infection of children | |
CN103705860B (en) | A kind of Chinese medicine composition for the treatment of infant jaundice and preparation method thereof | |
CN103948736B (en) | The compound Chinese medicinal preparation for the treatment of hepatocarcinoma and production method thereof | |
CN103041255A (en) | Chinese materia medica preparation for curing swollen sore throat and respiratory tract infection of children | |
CN103263658A (en) | Traditional Chinese medicine preparation for treating peripheral facial paralysis and preparation method thereof | |
CN105169278A (en) | Dandelion oral liquid capable of protecting liver and benefiting gallbladder and preparation method thereof | |
CN105169149A (en) | Traditional Chinese medicine composition for treating pyrophlegm stasis accumulation type thyroid cancer, preparation method and application | |
CN101549140B (en) | Traditional Chinese medicine composition for treating AIDS and preparation method thereof | |
CN104840773A (en) | Traditional Chinese medicine composition for treating vertebral artery type cervical spondylopathy and method for preparing same | |
CN104587342A (en) | Medicinal liquor suitable for being drunk by patients with hyperthyroidism and preparation process thereof | |
CN104491318A (en) | Traditional Chinese preparation used for treating asthma and preparation method of traditional Chinese preparation | |
CN105617319A (en) | Preparation method of traditional Chinese medicine composition for treating acute cholecystitis | |
CN103585434B (en) | Traditional Chinese medicine composition for treating anemia | |
CN105796951A (en) | External-use preparation used by radiology department for treating nasal polyp and preparation method | |
CN105288166A (en) | Traditional Chinese medicine composition for thyroid enlargement and preparation method thereof | |
CN104784646A (en) | Pharmaceutical composition for treating infantile hernia and preparation method of pharmaceutical composition | |
CN104958420A (en) | Traditional Chinese medicine for treating phlegm turbidity type migraine and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220401 Address after: 533011 room 507, 5 / F, building 8, phase II standard plant, No. 6, Yinhai Road, Youjiang District, Baise City, Guangxi Zhuang Autonomous Region Patentee after: Guangxi Yunqiu Biotechnology Co.,Ltd. Address before: Department of Biochemistry, Baise Road, Guangxi Zhuang Autonomous Region Patentee before: Zhang Shuqiu Patentee before: Liu Yan |
|
TR01 | Transfer of patent right |